口腔生物医学
口腔生物醫學
구강생물의학
ORAL BIOMEDICINE
2014年
3期
125-129
,共5页
肿瘤干细胞%放疗敏感性%鳞状细胞%肿瘤
腫瘤榦細胞%放療敏感性%鱗狀細胞%腫瘤
종류간세포%방료민감성%린상세포%종류
Neoplastic stem cells%Radiosensitivity%Squamous cell%Neoplasms
目的:探讨舌鳞状细胞癌中肿瘤干细胞对放疗的敏感性。方法:采用磁珠分选技术、细胞免疫荧光染色和细胞增殖活性试验等方法,研究经分选后得到的肿瘤干细胞和阴性细胞在放疗后细胞增殖活性方面的差异。结果:细胞免疫荧光结果显示,CD133和 CD44在分选出来的 CD133+/CD44+细胞高表达,而在 CD133-/CD44-细胞基本不表达。CCK8实验结果显示,分选出来的 CD133+/CD44+细胞较 CD133-/CD44-细胞在放疗的作用下具有更高的细胞相对增殖率。结论:经磁珠分选出来的舌癌肿瘤干细胞(CD133+/CD44+细胞)更能耐受放疗的作用。
目的:探討舌鱗狀細胞癌中腫瘤榦細胞對放療的敏感性。方法:採用磁珠分選技術、細胞免疫熒光染色和細胞增殖活性試驗等方法,研究經分選後得到的腫瘤榦細胞和陰性細胞在放療後細胞增殖活性方麵的差異。結果:細胞免疫熒光結果顯示,CD133和 CD44在分選齣來的 CD133+/CD44+細胞高錶達,而在 CD133-/CD44-細胞基本不錶達。CCK8實驗結果顯示,分選齣來的 CD133+/CD44+細胞較 CD133-/CD44-細胞在放療的作用下具有更高的細胞相對增殖率。結論:經磁珠分選齣來的舌癌腫瘤榦細胞(CD133+/CD44+細胞)更能耐受放療的作用。
목적:탐토설린상세포암중종류간세포대방료적민감성。방법:채용자주분선기술、세포면역형광염색화세포증식활성시험등방법,연구경분선후득도적종류간세포화음성세포재방료후세포증식활성방면적차이。결과:세포면역형광결과현시,CD133화 CD44재분선출래적 CD133+/CD44+세포고표체,이재 CD133-/CD44-세포기본불표체。CCK8실험결과현시,분선출래적 CD133+/CD44+세포교 CD133-/CD44-세포재방료적작용하구유경고적세포상대증식솔。결론:경자주분선출래적설암종류간세포(CD133+/CD44+세포)경능내수방료적작용。
Objective:To investigate the radiosensitivity of cancer stem cells in squamous cell cacinoma of tongue.Methods:CD1 33 +/CD44 +and CD1 33 -/CD44 -subpopulation cells were sorted by magnetic cell sorting (MACS).Single isolated CD1 33 +/CD44 +and CD1 33 -/CD44 -cell was cultured in RPMI-1 640 mediun,which contained 1 0 ng/mL basic fibroblast growth factor (bF-GF),and 20 ng/mL epidermal growth factor (EGF).Immunofluorescence was applied to detect the expression of CD1 33 and CD44 in these two subpopulation cells.CCK-8 assay was performed to analyze the radiosensitivity of the two subpopulations.Results:Cell im-munofluorescence showed that CD1 33 and CD44 could be detected in CD1 33 +/CD44 + cells while they could not be detected in CD1 33 -/CD44 -cells.Radiation therapy had a more obvious inhibitory effect on CD1 33 -/CD44 - cells than on CD1 33 +/CD44 +cells.Conclusions:The cancer stem cells in squamous cell carcinoma of tongue(CD1 33 +/CD44 +cells)that sorted by MACS showed strong capability of tumor′s resistance to radiation therapy than that of CD1 33 -/CD44 -cells.